Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022
Certara, a leader in biosimulation, will release its Q3 2022 financial results on November 7, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Certara, a leader in biosimulation, will release its Q3 2022 financial results on November 7, 2022, after market close. A conference call with management will follow at 5:00 p.m. ET to discuss the results. Interested investors must register online, ideally a day in advance. The event will be accessible via a live and archived webcast on the Certara website. The company aids over 2,000 clients globally in drug discovery and development through its innovative software and services.
Details
News Market Reaction – CERT
The recorded move for CERT in the trading session of this news was -1.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries. Visit us at www.certara.com.
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.